318 related articles for article (PubMed ID: 37256534)
1. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
Singh AM; Guevara-Patino JA; Wang X; Li R; Sonpavde G; Jain RK
BioDrugs; 2023 Jul; 37(4):505-520. PubMed ID: 37256534
[TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates for urothelial carcinoma.
Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
[TBL] [Abstract][Full Text] [Related]
3. Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives.
Alameddine R; Mallea P; Shahab F; Zakharia Y
Curr Treat Options Oncol; 2023 Sep; 24(9):1167-1182. PubMed ID: 37403009
[TBL] [Abstract][Full Text] [Related]
4. The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.
Abel M; Burkenroad A; Sun A; Lu E; Stefanoudakis D; Drakaki A
Clin Genitourin Cancer; 2021 Jun; 19(3):183-193. PubMed ID: 33558159
[TBL] [Abstract][Full Text] [Related]
5. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
Yu J; Wu S; Li R; Jiang Y; Zheng J; Li Z; Li M; Xin K; Guan X; Li S; Chen X
J Hematol Oncol; 2023 Jul; 16(1):85. PubMed ID: 37507780
[TBL] [Abstract][Full Text] [Related]
6. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
[TBL] [Abstract][Full Text] [Related]
7. [Antibody-drug conjugates as new therapeutic agents in uro-oncology].
Grimm MO; Foller S; Leeder M; Leucht K
Urologie; 2023 Jul; 62(7):679-684. PubMed ID: 37294330
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Resistance to Antibody-Drug Conjugates.
Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma.
Niegisch G
Methods Mol Biol; 2023; 2684():293-301. PubMed ID: 37410242
[TBL] [Abstract][Full Text] [Related]
10. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer.
Alhalabi O; Altameemi L; Campbell MT; Meric-Bernstam F
Cancer J; 2022 Nov-Dec 01; 28(6):417-422. PubMed ID: 36383903
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates in Urothelial Carcinomas.
Sarfaty M; Rosenberg JE
Curr Oncol Rep; 2020 Feb; 22(2):13. PubMed ID: 32008109
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
[TBL] [Abstract][Full Text] [Related]
16. Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.
Faltas B; Goldenberg DM; Ocean AJ; Govindan SV; Wilhelm F; Sharkey RM; Hajdenberg J; Hodes G; Nanus DM; Tagawa ST
Clin Genitourin Cancer; 2016 Feb; 14(1):e75-9. PubMed ID: 26541586
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside.
Ungaro A; Tucci M; Audisio A; Di Prima L; Pisano C; Turco F; Delcuratolo MD; Di Maio M; Scagliotti GV; Buttigliero C
Cells; 2022 Feb; 11(5):. PubMed ID: 35269424
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates in Uro-Oncology.
Sigorski D; Różanowski P; Iżycka-Świeszewska E; Wiktorska K
Target Oncol; 2022 May; 17(3):203-221. PubMed ID: 35567672
[TBL] [Abstract][Full Text] [Related]
19. [ANTIBODY-DRUG CONJUGATES - A NOVEL APPROACH FOR THE TREATMENT OF METASTATIC UROTHELIAL CARCINOMA].
Sternschuss M; Sarfaty M
Harefuah; 2022 Jan; 161(1):49-54. PubMed ID: 35077061
[TBL] [Abstract][Full Text] [Related]
20. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
